Todd C. Davis - 27 Feb 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Issuer symbol
LGND
Transactions as of
27 Feb 2024
Transactions value $
$0
Form type
4
Filing time
29 Feb 2024, 18:49:56 UTC
Previous filing
23 Feb 2024
Next filing
27 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +32.4K +45.23% $0.00 104K 27 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Award $0 +132K $0.00 132K 27 Feb 2024 Common Stock 132K $89.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2 The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.